Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,21The interpretation and reporting of the data presented here are the responsibility of the authors, and in no way should be seen as an official policy or interpretation of the United States government.2See Editorial by Orth and Uehlinger, p. 1580.  by Foley, Robert N. et al.
Kidney International, Vol. 63 (2003), pp. 1462–1467
Smoking and cardiovascular outcomes in dialysis patients:
The United States Renal Data System Wave 2 Study1,2
ROBERT N. FOLEY, CHARLES A. HERZOG, and ALLAN J. COLLINS
Cardiovascular Special Studies Center, United States Renal Data System, Minneapolis, Minnesota
Smoking and cardiovascular outcomes in dialysis patients: The from the Framingham Heart Study and other observa-
United States Renal Data System Wave 2 Study. tional studies, that much of the etiology of atheroscle-
Background. Smoking has received surprisingly little re- rotic cardiovascular disease relates to modifiable livingsearch attention in dialysis populations, a group at monumental
habits. Smoking is the archetypal example [1]. For exam-cardiovascular risk.
ple, the Framingham Heart Study has reported 20-yearMethods. Medicare claims data were used to study associa-
tions between smoking and new-onset cardiovascular outcomes, trends in risk factors and cardiovascular mortality among
and death in the prospective, inception Wave 2 cohort (N  members of the study aged 50 to 59 years old in 1950,
4024), assembled in 1996 and 1997.
1960, and 1970. Cardiovascular disease mortality de-Results. Of the participants, 56.4% were lifetime nonsmok-
clined by over 50%, over half of which was explaineders, 3.6% were smokers with unknown current status, 20.0%
had quit for more than 1 year, 5.8% had quit less than 1 year by changes in modifiable risk factors like smoking [2].
ago, and 14.2% were current smokers. Subjects with cardiovas- The cardiovascular and cancer risks associated with
cular disease at baseline were more likely to be former smokers, smoking in the general population are widely appreci-
less likely never to have smoked and less likely to be current
ated [3, 4]. In contrast, smoking has received little atten-smokers (P  0.001). Patients were followed until December
tion as a cardiovascular risk factor in end-stage renal31, 1998. When adjustment was made for baseline age, demo-
graphic variables, mode of dialysis therapy, and comorbidity, disease, and smoking cessation is rarely emphasized in
smoking status was associated with new-onset congestive heart the burgeoning literature describing the interactions be-
failure (adjusted hazards ratio 1.59 comparing current to non- tween cardiovascular and renal disease. A number of re-smokers, P  0.004), new-onset peripheral vascular disease
cent studies have examined the cross-sectional associations(adjusted hazards ratio 1.68, P  0.001), and mortality (ad-
of cardiovascular syndromes in dialysis populations. Smok-justed hazards ratio 1.37, P  0.001). Former smokers, in con-
trast, had adjusted event risks similar to lifelong nonsmokers. ing status has been associated with the presence of coro-
Conclusion. Smoking is a major, modifiable, cardiovascular nary artery disease and peripheral vascular disease [5, 6].
risk factor in patients starting dialysis therapy. Although these are findings are suggestive, and consis-
tent with findings from the general population, an obvi-
ous weakness of cross-sectional designs is that the find-
Atherosclerotic cardiovascular disease in the general ings reflect past history, with past smoking behavior
population is a complex interaction of many factors. An linked to cardiovascular problems that have already de-
incomplete list could include genetic factors, lipid fac- veloped. Prospective associations with future cardiovas-
tors, pressure factors, rheologic forces, carbohydrate tol- cular syndromes, especially when these occur for the first
erance, redox status, inflammatory activation, and hemo- time, might provide a greater incentive to alter risky
static factors. It has been known for at least 40 years, lifestyle practices, even at a relatively late stage of pro-
gressive renal disease.
1 The interpretation and reporting of the data presented here are the
responsibility of the authors, and in no way should be seen as an official
METHODSpolicy or interpretation of the United States government.
The Dialysis Morbidity and Mortality Study (DMMS)2 See Editorial by Orth and Uehlinger, p. 1580.
was an observational study in which demographic, co-
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Table 1. The Dialysis Morbidity and Mortality Study (DMMS) 2 patients with United States Renal Data System (USRDS) identification number
Adjusted odds ratio
All Without cardiovascular With cardiovascular (95% CI) for presence of
(N  3941) diseasea (48.2%) diseasea (51.8) cardiovascular diseasea,b
Smoking status
Nonsmoker (reference group) 56.4% 60.7% 52.4% 1 (reference)
Smoker, status unknown 3.6% 3.7% 3.4% 1.11 (0.73,1.69)
Former, stopped  1 year 20.0% 14.0% 25.5% 1.61 (1.31,1.97)
Former, stopped  1 year 5.8% 4.9% 6.6% 1.61 (1.15,2.26)
Active 14.2% 16.7% 12.0% 1.21 (0.96,1.52)
P  0.001 P  0.001
Age years 58.4 (57.9, 58.9) 52.0 (51.3, 52.7) 64.3 (63.7, 64.9) 1.06 (1.05,1.06)
P  0.001 P  0.001
Gender
Male (reference group) 52.8% 52.3% 53.2% 1
Female 47.2% 47.7% 46.8% 0.92 (0.79,1.08)
P  0.6 P  0.3
Race
Caucasian (reference group) 63.0% 56.9% 68.7% 1
African American 28.4% 32.9% 24.1% 0.74 (0.62,0.89)
Asian 2.8% 3.7% 2.0% 0.42 (0.26,0.68)
Native 1.2% 1.1% 1.2% 1.17 (0.58,2.38)
Other 4.7% 5.4% 4.0% 0.61 (0.40,0.91)
P  0.001 P  0.001
Hispanic 10.0% 10.1% 10.0% 0.93 (0.69,1.25)
P  1.0 P  0.6
Primary renal disorder
Diabetes mellitus (reference group) 43.5% 32.5% 53.6% 1
Hypertension 26.1% 27.9% 24.5% 0.79 (0.58,1.07)
Glomerulonephritis 8.5% 12.4% 4.8% 0.54 (0.36,0.80)
Other/unknown 22.0% 27.2% 17.1% 0.74 (0.54,1.02)
P  0.001 P  0.02
Coronary heart disease 32.4% — — —
Congestive heart failure 34.9% — — —
Cerebrovascular disease 10.2% — — —
Peripheral vascular disease 16.9% — — —
Diabetes mellitus 49.4% 36.1% 61.6% 2.34 (1.75,3.13)
P  0.001 P  0.001
Mode of dialysis
Hemodialysis (reference group) 51.2% 45.1% 56.9% 1
Peritoneal dialysis 48.8% 54.9% 43.1% 0.75 (0.65,0.88)
P  0.001 P  0.001
a“Cardiovascular disease” is defined as the presence of coronary heart disease, congestive heart failure, cerebrovascular disease or peripheral vascular disease at
initiation of dialysis therapy. P values refer to the comparison of subjects with baseline cardiovascular disease and subjects without cardiovascular disease.
bUsing logistic regression
and 1997. All patients initiating peritoneal dialysis and cardiovascular events. Smoking status in the Wave 2 study
one fifth of patients initiating hemodialysis were included, was arbitrarily classified into the following groups: (1)
with over-sampling of peritoneal dialysis patients used as nonsmoker; (2) smoker, status unknown; (3) former
a strategy to produce similar numbers of patients as on smoker, quit more than 1 year; (4) former smoker, quit
hemodialysis. The study start date for the DMMS Wave less than 1 year; and (5) active smoker.
2 began 60 days following the initiation of chronic dial- Pack-years of smoking were not calculated as part of
ysis. The DMMS Wave 2 dataset, which included 4024 the initial data collection. The unique USRDS identifi-
subjects, was linked with the United States Renal Data cation number was used to identify admissions for major
System (USRDS), a renal registry that captures data on cardiovascular events occurring after initiation of dialysis
all patients undergoing dialysis in the United States, us- therapy from Medicare claims records. The following
ing the unique USRDS number. Of the 4024 patients in
events were studied, using International Classificationthe Wave 2 dataset, 83 lacked a USRDS number, so that
of Diseases, 9th edition (ICD-9) codes, described in de-the number of patients used in this study was 3941 (98%).
tail in the Appendix; coronary heart disease, congestiveThe major objective of this study was to test for associ-
heart failure, stroke, peripheral vascular disease, andations between smoking status and new-onset cardiovas-
death. All baseline data, including the presence of acular events occurring after initiation of dialysis therapy.
given cardiovascular condition at inception of dialysis,Incident events were chosen in an effort to reduce the
were obtained from the prospective Wave 2 question-possibility of reverse causation, as it was thought plausi-
ble that smoking status could change in response to major naire data. ICD-9 codes were used to define new events.
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Fig. 1. Flow diagram of patients and cardiovascular events. Abbreviations are: CHD, coronary heart disease; CHF, congestive heart failure; CVA,
cerebrovascular disease; and PVD, peripheral vascular disease.
For example, new ischemic heart disease implies that congestive heart failure, cerebrovascular disease, or pe-
ripheral vascular disease, at initiation of dialysis therapy.question B3a “Prior diagnosis of coronary artery disease
The group with cardiovascular disease at baseline con-(CAD)/coronary heart disease (CHD)” was coded as
tained fewer lifelong nonsmokers, and more former“no” while an admission after the start of dialysis therapy
smokers than those without cardiovascular disease. Lo-included one of the ICD-9 codes numbered 410, 410x,
gistic regression analysis, also shown in Table 1, sug-410xx, 411, 411x, 411xx, where x is between 0 and 9.
gested that the association between smoking status andMultivariate logistic regression was used to assess
baseline cardiovascular disease was independent of age,whether any association between smoking status and car-
gender, racial group, ethnic group, primary renal disease,diovascular disease at initiation of dialysis therapy was
the presence or absence of diabetes, and the mode ofindependent of baseline age and comorbidity. Cox regres-
dialysis therapy.
sion was used to test for associations between baseline The flow diagram in Figure 1 shows that over a mean
smoking status, new-onset cardiovascular events, and duration of follow-up of 2.2 years, the incidence of new
death. Adjustment for insurance provider had no impact acute coronary syndrome, congestive heart failure, stroke
on our findings and was not included as a covariate in and peripheral vascular disease were 10.2%, 13.6%,
this report. Follow-up for these analyses was until Decem- 2.2%, and 14%, respectively. A total of 36.1% of subjects
ber 31, 1998 and an-intention-to-treat philosophy was died during this time.
taken with respect to mode of renal replacement therapy, Table 2 shows the incidence of new-onset cardiovascu-
lar events from hospitalization claims data. Currentso that analysis ignored switches of dialysis therapy, and
smoking at study inception was associated with increasedtransplantation was not considered a censoring event.
rates of new-onset congestive heart failure, new-onset
peripheral vascular disease, and shorter survival. These
RESULTS associations with new-onset congestive heart failure
(hazards ratio 1.58, P  0.008), new-onset peripheralThe characteristics of the study subjects are shown in
vascular disease (hazards ratio 1.68, P  0.001), andTable 1. Of the total, 56.4% were lifetime nonsmokers,
death (hazards ratio 1.37, P  0.001) persisted after3.6% were classified as being smokers whose current
adjustment for baseline age, demography, comorbidity,status was unknown, 20.0% were former smokers who
and mode of dialysis therapy.had quit more than 1 year ago, 5.8% were former smok-
ers who had quit less than 1 year ago, and 14.2% were
DISCUSSIONcurrently active smokers. Table 1 also shows a compari-
son between subjects with or without cardiovascular dis- In this study, both the percentage of lifetime nonsmok-
ers (56%) and current smokers (14.2%) were much lowerease, defined as the presence of coronary heart disease,
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than the percentage of adult smokers in the United States greater in current smokers compared with ex-smokers
and never-smokers. In contrast, the outcome rates of ex-in 1996 and 1997 (24.7%) [7]. This finding was somewhat
surprising, and it is plausible that a degree of underre- smokers and never-smokers were similar, suggesting, as
does this report, that quitting at a late disease phase canporting of smoking behavior to the data collection per-
sonnel may have occurred. We found that subjects with still improve outcomes [11]. Smoking has been shown to
increase heart rate, decrease stroke volume, and increasecardiovascular disease at dialysis inception were more
likely to be former smokers, suggesting the following systemic blood pressure, pulmonary capillary wedge pres-
sure, and myocardial oxygen consumption in patientspotential sequence of events prior to the onset of end-
stage renal disease: smoking, cardiovascular event, dis- with congestive heart failure [12]. It is possible that the
somewhat disparate findings, with smoking associatedcontinuation of smoking. The cross-sectional nature of
these findings means that temporal sequencing, an oblig- with certain cerebrovascular syndromes, and not with
others, may reflect the fact that both silent myocardialatory prerequisite in the process of showing causal likeli-
hood, is impossible. This study also examined cardiovas- ischemia, and symptomatic ischemia with normal coro-
nary arteries are frequent in patients with end-stage renalcular syndromes occurring for the first time after inception
of dialysis therapy. When adjustment was made for base- disease [13, 14].
This study has several obvious limitations. Pack-yearsline age, demographic variables, mode of dialysis ther-
apy, and comorbidity, current smoking was associated at the time of inception of dialysis were not measured.
Similarly, smoking behavior after inception of renal re-with new-onset congestive heart failure, new-onset pe-
ripheral vascular disease, and mortality. Former smok- placement therapy was not captured. Given the age of
the population, which averaged 58 years, it is likely thaters, in contrast, had adjusted event risks similar to life-
long nonsmokers. Again, these findings cannot prove a current smokers had higher exposures than ex-smokers
and nonsmokers. ICD-9 codes admission codes werecausal link, but at least have the advantage of demonstra-
ting a temporal sequence whereby assessment of the used to define cardiovascular events. Predefined clinical
outcomes, monitored in real time, with blinded centralputative risk factor predates the outcomes being studied.
If these findings reflect cause and effect, they suggest outcome evaluation were not employed. To date, very
little end-stage renal disease–specific research has beenthat smoking cessation can reduce cardiovascular risk in
dialysis patients. performed to compare the use of ICD admission codes
Smoking has been linked with death in United States with this ideal approach. Despite its limitations, however,
hemodialysis patients [8], mirroring the well-known asso- this study suggests that smoking is linked to a higher
ciation between cigarette smoking, cancer, and cardio- incidence of cardiovascular disease and death in a popu-
vascular disease in the general population. A study of lation at enormous cardiovascular risk. These findings
1334 renal transplant patients in the United States found suggest that efforts to encourage patients to stop smoking
that the prevalence of smoking at the time of transplanta- can abrogate the risk of cardiovascular disease in popula-
tion was as high as in the general population. Smoking tion with renal impairment.
at transplantation was associated with a higher risk of
Reprint requests to Dr. Robert N. Foley, 914 South Eighth Street,graft failure, major cardiovascular events, invasive malig- Suite D-253, Minneapolis, MN 55404, USA.
nancies, and death. It was noteworthy that cardiovascu- E-mail: RFoley@nephrology.org
lar risk was reduced in those who stopped smoking 5 or
more years before transplantation [9]. Several studies,
APPENDIXin heterogeneous patient populations suggest that smok-
ICD-9 codes used to define cardiovascular eventsing is associated with accelerated rates of loss of renal
function [10]. 1. Coronary heart disease, defined as either acute myocardial in-
farction with ICD-9 codes numbered 410, 410x, 410xx where x is be-The association between smoking and peripheral vas-
tween 0 and 9) or unstable angina (claims numbered 411, 411x, 411xxcular disease observed in this study is not unexpected. where x is between 0 and 9).
It is unclear, however, why smoking would predispose 2. Congestive heart failure (ICD-9 codes 425, “Cardiomyopathy”;
4259, “Secondary cardiomyopathy, unspecified”; 428, “Heart failure”;to cardiac failure and peripheral vascular disease, but
4280, “Congestive heart failure”; 4281, “Left heart failure”; 4289,not to acute coronary syndromes or stroke. It is tempting
“Heart failure, unspecified”; 4291, “Myocardial degeneration”; 40201,
to speculate that the relatively small number of strokes “Hypertensive heart disease, malignant, with congestive heart failure”;
40211, Hypertensive heart disease, malignant, with congestive heartobserved may have led to a Type II error. It is well known
failure”; and 40291, “Hypertensive heart disease, unspecified, withthat smoking can exacerbate cardiac failure in the gen-
congestive heart failure”).
eral population. For example, in the Study Of Left Ven- 3. Stroke (ICD-9 codes 430, “Subarachnoid hemorrhage”; 431, “In-
tracerebral hemorrhage”; 432, “Other and unspecified intracranialtricular Dysfunction (SOLVD) Prevention and Interven-
hemorrhage”; 4320, “Nontraumatic extradural hemorrhage”; 4321,tion trials, in which the study subjects had left ventricular
“Nontraumatic subdural hemorrhage”; 4329, “Unspecified intracranial
ejection fraction less than 35%, the risks of congestive hemorrhage”; 433, “Occlusion and stenosis of precerebral arteries”;
4330, “Basilar artery”; 4331, “Carotid artery”; 4333, “Multiple or bilat-heart failure requiring hospitalization were significantly
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eral”; 4339, “Unspecified precerebral artery”; 434, “Occlusion of cere- REFERENCES
bral arteries”; 4341, “Cerebral embolism”; and 4349, “Cerebral artery
1. Freund KM, Belanger AJ, D’Agostino RB, Kannel WB: Theocclusion, unspecified”).
health risks of smoking. The Framingham Study: 34 years of follow-4. Peripheral vascular disease (ICD-9 codes 440, “Atherosclerosis”;
up. Ann Epidemiol 3:417–424, 19934400, “Atherosclerosis of aorta”; 4402, “Atherosclerosis of native arter-
2. Sytkowski PA, D’Agostino RB, Belanger A, Kannel WB: Sexies of the extremities”; 44020, “Atherosclerosis of the extremities,
and time trends in cardiovascular disease incidence and mortality:unspecified”; 44021, “Atherosclerosis of the extremities with intermit-
The Framingham Heart Study, 1950–1989. Am J Epidemioltent claudication”; 44022, “Atherosclerosis of the extremities with rest 143:338–350, 1996
pain”; 44023, “Atherosclerosis of the extremities with ulceration”; 3. Bartecchi CE, MacKenzie TD, Schrier RW: The human costs
44024, “Atherosclerosis of the extremities with gangrene”; 4403, “Ath- of tobacco use (1). N Engl J Med 330:907–912, 1994
erosclerosis of bypass graft of the extremities”; 44030, “Atherosclerosis 4. MacKenzie TD, Bartecchi CE, Schrier RW: The human costs
of bypass graft of the extremities, unspecified graft”; 44031, “Athero- of tobacco use (2). N Engl J Med 330:975–980, 1994
sclerosis of bypass graft of the extremities, autologous vein bypass 5. Stack AG, Bloembergen WE: Prevalence and clinical correlates of
graft”; 44032, “Atherosclerosis of bypass graft of the extremities, non- coronary artery disease among new dialysis patients in the United
States: A cross-sectional study. J Am Soc Nephrol 12:1516–1523,autologous vein bypass graft”; 4408, “Atherosclerosis of other specified
2001noncranial arteries”; 4409, “Atherosclerosis, generalized and unspeci-
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